Dream Pharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Dream Pharma - overview
Established
1995
Location
Seoul, -, South Korea
Primary Industry
Pharmaceuticals
About
Dream Pharma is a pharmaceutical company dedicated to the development and distribution of innovative medications, addressing a variety of health challenges through advanced biopharmaceutical technologies. Founded in 1995 and headquartered in Seoul, South Korea, Dream Pharma specializes in pharmaceutical product development and distribution. The company underwent a significant change when Alvogen, Inc. acquired it for USD 187 mn in August 2014.
The current CEO is Vasil Zguri, who previously founded other ventures. Dream Pharma is engaged in the development and distribution of pharmaceutical products aimed at addressing various health challenges. The company’s primary offerings include a range of prescription medications and over-the-counter treatments, focusing on therapeutic areas such as chronic diseases, infectious diseases, and pain management. By leveraging advanced biopharmaceutical technologies, Dream Pharma aims to enhance patient outcomes through innovative formulations designed for improved efficacy and safety.
The products are primarily targeted towards healthcare providers, hospitals, and pharmacies, with end users including patients requiring effective treatment options. Dream Pharma operates in key international markets, including North America, Europe, and parts of Asia, ensuring a broad reach for its product offerings. In the most recent fiscal year of 2014, Dream Pharma reported a revenue of USD 24,468,409 and an EBITDA of USD 446,018,921. 4.
The company generates revenue through a structured model that includes direct sales to healthcare institutions and pharmacies, as well as partnerships with wholesalers, predominantly through B2B arrangements. Dream Pharma plans to leverage its recent acquisition to expand its product offerings. As noted in the acquisition deal signed in August 2014, the company is set to utilize the USD 187 mn investment from Alvogen to support new product development aimed at addressing specific health needs. The company is also strategizing to enter new markets, with particular focus on expanding its presence in Europe and parts of Asia by 2025.
Current Investors
Alvogen
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.dreampharma.co.kr
Verticals
Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Dream Pharma - financials
| Fiscal Year Ended | Dec 31, 2014 |
|---|---|
| Revenue (USD) | - |
| % Revenue Growth (YoY) | - |
| EBITDA (USD) | - |
| Operating Income (USD) | - |
| Operating Margin | - |
| % EBITDA Margin | - |
| NET Income (USD) | - |
| % Net Margin | - |
Dream Pharma - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Dream Pharma | - |
Displaying 1 - 1 of 1
Dream Pharma - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.